S
Spyre Therapeutics D
D
SYRE
106.580
USD
-1.28
(-1.19%)
مغلق
حجم التداول
0
الربح لكل سهم
-3
العائد الربحي
-
P/E
-56
حجم السوق
9,397,559,554
العنوان: Spyre Therapeutics
القطاع: الرعاية الصحية
الصناعة: Biotechnology
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting 47, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
